A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma
This is a phase 1 study to evaluate the safety and determine maximum tolerated dose, safety \& tolerability of noscapine HCl in patients with advanced multiple myeloma
Refractory Multiple Myeloma
DRUG: Noscapine HCl
To determine the maximum tolerated dose, During the first 28 day treatment cycle
To determine the safety and tolerability in the study population, End of the study treatment|To evaluate the pharmacokinetics of study drug, End of the study treatment|To assess anti-tumor effects as classified by International Uniform Response Criteria for Multiple Myeloma, End of the study treatment
This is a phase 1 study to evaluate the safety and determine maximum tolerated dose, safety \& tolerability of noscapine HCl in patients with advanced multiple myeloma